Renewed GMP certification for China Biologic Products' Qianfeng subsidiary

Sep 29 2009

China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.

Qianfeng is one of the largest plasma-based biopharmaceutical companies in China located in Guiyang, Guizhou Province, with 400 tons of annual production capacity for blood-based products. Qianfeng's production facility was certified to be in compliance with the requirements of the SFDA's GMP for pharmaceutical products on September 1, 2009. The GMP certification is valid for five years and will be subject to renewal in September 2014. China Biologic owns a controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd., which, in turn, owns a controlling equity interest in Qianfeng.

"We are pleased that our newly acquired subsidiary's production facility continues to be in compliance with the SFDA's GMP standards, which are in compliance with our commitment to the maintenance of high quality standards in the plasma and blood products industry," said Mr. Chao Ming Zhao, the Company's CEO. "We believe that there are only 32 GMP approved biopharmaceutical companies in China, including our three indirect subsidiaries, which are all currently in compliance with these standards."